Author name: Ataxia Foundation

Biohaven has announced FDA approval for Troriluzole Biohaven has announced that the U.S. Food and Drug Administration (FDA) has accepted […]

Friedreich’s ataxia (FA) is a rare, progressive neurological disorder that affects coordination, balance, and muscle strength. It is caused by

Latest Updates in Friedreich’s Ataxia Drug Development The landscape of Friedreich’s ataxia (FA) drug development is evolving rapidly, with multiple

Introduktion Omaveloxolon, kommersiellt känt som Skyclarys, är det första godkända läkemedlet specifikt utvecklat för att behandla Friedreichs ataxi (FA), en

Nov 12 – Nov 15th 2024, London United Kingdom Hosted by FARA, NAF, AGI and Ataxia UK The International Congress